Dana-Farber Cancer Institute is set to present a range of significant cancer research findings at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, from September 13-17. The studies encompass novel treatments, including targeted therapies and antibody-drug conjugates, alongside research aimed at enhancing the quality of life for breast cancer patients.
Ann Partridge, MD, MPH, founder and director of the Program for Young Adults with Breast Cancer at Dana-Farber, will receive The ESMO Award during the opening session on September 13, 2024, recognizing her contributions to breast cancer research and patient care.
DESTINYBreast-12: Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer
Nancy Lin, MD, associate chief of breast oncology at Dana-Farber, will present primary results from the pivotal DESTINYBreast-12 study (LBA18). This research investigates the efficacy of trastuzumab deruxtecan in patients with HER2-positive advanced or metastatic breast cancer, including those with brain metastasis. The findings will be shared as a late-breaking abstract during the Proffered Paper Session: Breast Cancer, metastatic, on Friday, September 13, 2024.
TiNivo-2 Study: Tivozanib-Nivolumab in Renal Cell Carcinoma
Toni Choueiri, MD, director of the Lank Center for Genitourinary Cancer, will present data from the Phase 3 TiNivo-2 Study (LBA73). This study evaluates the combination of tivozanib and nivolumab compared to tivozanib monotherapy in patients with renal cell carcinoma who have previously undergone therapies, including immune checkpoint inhibitors. The presentation will occur during the Proffered Paper Session 1: GU tumors, non-prostate, on Friday, September 13, 2024.
SOLARIS (Alliance A021703): Vitamin D Supplementation in Metastatic Colorectal Cancer
Kimmie Ng, MD, MPH, associate chief of gastrointestinal oncology at Dana-Farber, will present data from the SOLARIS study (LBA26), a multicenter, double-blind, Phase III randomized clinical trial. This trial examines the impact of high-dose vitamin D supplementation combined with standard chemotherapy and bevacizumab in patients with previously untreated metastatic colorectal cancer. Jeffrey Meyerhardt, MD, MPH, co-director of the colon and rectal cancer center at Dana-Farber, is the senior author. Ng will present the findings during the Proffered Paper Session 2: GI tumors, lower, on Saturday, September 14, 2024.
Additional Key Research
Further research to be presented by Dana-Farber includes:
- NKT2152 in Advanced Clear Cell Renal Carcinoma (accRCC): Preliminary results of a Phase 1/2 study (1690O) of NKT2152, a novel oral HIF-2α inhibitor, in participants with previously treated accRCC. Toni Choueiri, MD, is the senior author.
- CFT1946 in Mutant BRAF V600 Solid Tumors: Preliminary results from a Phase 1 study (612O) of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors. Elizabeth Buchbinder, MD, is the senior author.
- Encorafenib Plus Binimetinib in BRAF V600E-Mutant Metastatic NSCLC (mNSCLC): Updated efficacy and safety data from the Phase 2 PHAROS study (LBA56) of encorafenib plus binimetinib in patients with BRAF V600E-mutant mNSCLC. Bruce Johnson, MD, is the senior author.
- Breastfeeding in Women with HR-Positive Breast Cancer: Results from the POSITIVE trial (1814O) on breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy. Ann Partridge, MD, MPH, is a co-senior investigator.
- Breastfeeding After Breast Cancer in BRCA Carriers: Results from an international cohort study (1815O) on breastfeeding after breast cancer in young BRCA carriers. Ann Partridge, MD, MPH, is a co-senior investigator.
- Weight Loss Intervention and Exercise in Women with Breast Cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (1817MO) on the effect of a weight loss intervention on exercise behaviors in women with breast cancer. Jennifer Ligibel, MD, is the presenting author.
- Rinatabart Sesutecan (Rina-S) in Advanced Ovarian or Endometrial Cancer: A Phase 1/2 study (719MO) of Rinatabart Sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer. Elizabeth Lee, MD, is the presenting author.
- Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET): Updated results including progression-free survival (PFS) by blinded independent central review (BICR) and subgroup analyses from the CABINET Trial/Alliance A021602 (1141O) evaluating cabozantinib versus placebo after progression on prior therapy. Jennifer Chan, MD, MPH, is the presenting author, and Jeffrey Meyerhardt, MD, MPH, is the senior author.
